Fresenius SE & Co. KGaA Cash Flow Conversion Efficiency
Fresenius SE & Co. KGaA cash flow conversion efficiency. Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€756.00 Million ≈ $883.84 Million USD) by net assets (€19.27 Billion ≈ $22.53 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Fresenius SE & Co. KGaA (FRE) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Fresenius SE & Co. KGaA (2002–2024)
Cash flow conversion efficiency of Fresenius SE & Co. KGaA from 2002 to 2024. This chart illustrates how Fresenius SE & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Fresenius SE & Co. KGaA (FRE) share price today for real-time trading data and today's change.
Fresenius SE & Co. KGaA Cash Flow Conversion Ratio Explained
Fresenius SE & Co. KGaA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fresenius SE & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fresenius SE & Co. KGaA ranked by their cash flow conversion efficiency. Review free cash flow generation of Fresenius SE & Co. KGaA to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Givaudan SA
SW:GIVN
|
0.035x |
|
Fiserv Inc.
NASDAQ:FISV
|
0.081x |
|
FANUC CORP.UNSP.ADR 1/10
F:FUCA
|
N/A |
|
Celltrion Inc
KO:068270
|
0.023x |
|
KONE Oyj
HE:KNEBV
|
0.129x |
|
HOCHTIEF Aktiengesellschaft
F:HOT
|
0.694x |
|
IMPERIAL BRANDS PLC ADR/1
F:ITBA
|
N/A |
|
Okta Inc
NASDAQ:OKTA
|
0.034x |
Annual Cash Flow Conversion Efficiency for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual cash flow conversion efficiency of Fresenius SE & Co. KGaA from 2002 to 2024. Also see total assets of Fresenius SE & Co. KGaA for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.121x | -46.81% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
€4.46 Billion ≈ $5.21 Billion |
0.227x | +74.03% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.130x | -24.85% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
€5.08 Billion ≈ $5.94 Billion |
0.173x | -31.11% |
| 2020-12-31 | €26.02 Billion ≈ $30.42 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.252x | +56.91% |
| 2019-12-31 | €26.58 Billion ≈ $31.07 Billion |
€4.26 Billion ≈ $4.98 Billion |
0.160x | +7.19% |
| 2018-12-31 | €25.01 Billion ≈ $29.24 Billion |
€3.74 Billion ≈ $4.37 Billion |
0.150x | -17.45% |
| 2017-12-31 | €21.72 Billion ≈ $25.39 Billion |
€3.94 Billion ≈ $4.60 Billion |
0.181x | +9.57% |
| 2016-12-31 | €21.60 Billion ≈ $25.26 Billion |
€3.57 Billion ≈ $4.18 Billion |
0.165x | -5.77% |
| 2015-12-31 | €18.95 Billion ≈ $22.15 Billion |
€3.33 Billion ≈ $3.89 Billion |
0.176x | +9.78% |
| 2014-12-31 | €16.16 Billion ≈ $18.90 Billion |
€2.58 Billion ≈ $3.02 Billion |
0.160x | -5.34% |
| 2013-12-31 | €13.73 Billion ≈ $16.05 Billion |
€2.32 Billion ≈ $2.71 Billion |
0.169x | -8.83% |
| 2012-12-31 | €13.16 Billion ≈ $15.38 Billion |
€2.44 Billion ≈ $2.85 Billion |
0.185x | +16.05% |
| 2011-12-31 | €10.58 Billion ≈ $12.37 Billion |
€1.69 Billion ≈ $1.97 Billion |
0.160x | -26.10% |
| 2010-12-31 | €8.84 Billion ≈ $10.34 Billion |
€1.91 Billion ≈ $2.23 Billion |
0.216x | +6.47% |
| 2009-12-31 | €7.65 Billion ≈ $8.95 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.203x | +31.20% |
| 2008-12-31 | €6.94 Billion ≈ $8.12 Billion |
€1.07 Billion ≈ $1.26 Billion |
0.155x | -60.16% |
| 2007-12-31 | €3.34 Billion ≈ $3.90 Billion |
€1.30 Billion ≈ $1.52 Billion |
0.388x | +14.48% |
| 2006-12-31 | €3.10 Billion ≈ $3.63 Billion |
€1.05 Billion ≈ $1.23 Billion |
0.339x | +20.70% |
| 2005-12-31 | €2.78 Billion ≈ $3.25 Billion |
€780.00 Million ≈ $911.90 Million |
0.281x | -47.07% |
| 2004-12-31 | €1.60 Billion ≈ $1.87 Billion |
€851.00 Million ≈ $994.91 Million |
0.531x | +119.88% |
| 2003-12-31 | €3.21 Billion ≈ $3.76 Billion |
€776.00 Million ≈ $907.23 Million |
0.241x | +16.70% |
| 2002-12-31 | €3.37 Billion ≈ $3.94 Billion |
€697.00 Million ≈ $814.87 Million |
0.207x | -- |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more